Further Independent Support for Veyonda as a Major I-O Drug

Noxopharm Limited. ABN 50 608 966 123 Suite 3, Level 4, 828 Pacific Highway, Gordon NSW 2072 AUSTRALIA ASX Announcement | 18 November 2020 Noxopharm Limited (ASX:NOX) Independent Studies Continue To Support Role of Veyonda as Major Immuno- Oncology Drug Highlights: • Idronoxil (IDX), the active ingredient in Veyonda, confirmed as promoting migration of active immune cells into tumour structures • Action achieves major industry goal of restoring cancer-fighting function to tumour structures • Validates key COLD to HOT tumour conversion function of Veyonda Sydney 18 November 2020: Australian clinical -stage drug development company Noxopharm Limited (ASX:NOX) is pleased to announce that ongoing studies by independent university researchers continue to support the Company’s confidence in its lead drug candidate, Veyonda, becoming an important new immuno-oncology drug. The results of the study were presented to the Annual Meeting of the Clinical Oncology Society of Australia (COSA), Australia’s premiere cancer conference (11-13 November,2020). Noxopharm currently is developing Veyonda as a next -generation immunotherapy drug that works by restoring immune function to tumours, a fundamental step in efforts to make all forms of cancer therapy, including chemotherapy, radiotherapy and checkpoint inhibitor therapies, work more effectively. The Company is employing this ability to boost the effectiveness of radiotherapy (DARRT and LuPIN programs), checkpoint inhibitors (IONIC program) and standard chemotherapy drugs (CEP program). Graham Kelly, Noxopharm CEO and Managing Director, said, “Data such as this continues to underpin our belief in the potential of Veyonda to become a major new cancer therapy.” “We are working to position Veyonda as a next generation immunotherapy drug that works by restoring immune function to tumours, a fundamental step in ongoing industry efforts to make cancers respond more effectively to all forms of cancer therapy including chemotherapy, radiotherapy and immuno-oncology therapies. The lack of effective immune function within most human cancers is thought to be a key factor in modern medicine failing to make significant inroads into the treatment of most patients with metastatic disease. Restoring immune function, a process referred to in the industry as converting tumours from cold to hot, therefore has Noxopharm Limited. ABN 50 608 966 123 Suite 3, Level 4, 828 Pacific Highway, Gordon NSW 2072 AUSTRALIA become an important goal in oncology. This data nicely shows that this is exactly what idronoxil, the active ingredient in Veyonda, does very effectively.” “Given the considerable prize at stake, Noxopharm is not alone in looking to achieve this cold to hot outcome. However, those competitive technologies mostly require drug s to be injected directly into tumours. This presents obvious practical problems when the tumours are within the chest or abdomen or pelvis or bone which account for most cancer patients. Veyonda has the advantage of having no such limitations, reaching tumours via the bloodstream, which along with the high tolerability of Veyonda, leads us to believe that we have a major competitive advantage,” Kelly added. The poster presented at this year’s COSA conference entitled “Idronoxil combined with cisplatin rescues refractory immune responses in nasopharyngeal carcinoma”, will be available shortly on the Company’s website at: https://www.noxopharm.com/site/our-science/publications Graham Kelly, CEO and Managing Director of Noxopharm, has approved the release of this document to the market on behalf of the Board of Directors. -ENDS- About Noxopharm Noxopharm Limited (ASX:NOX) is an Australian clinical-stage drug development company focused on the treatment of cancer and septic shock. Veyonda® is the Company’s first pipe-line drug candidate currently in Phase 2 clinical trialling. Veyonda ® has two main drug actions – inhibition of sphingosine kinase and inhibition of STING signalling. Activity against the former target contributes to its dual-acting oncotoxic and immuno-oncology functions designed to enhance the effectiveness and safety of standard oncology treatments, i.e., chemotherapies, radiotherapy and immune checkpoint inhibitors. Activity against the latter target provides an anti-inflammatory effect, also contributing to an anti-cancer action, but also potentially blocking sepsis. Noxopharm also is the major shareholder of US biotechnology company Nyrada Inc (ASX:NYR). To learn more, please visit: noxopharm.com Investor & Corporate enquiries: Company Secretary: Prue Kelly David Franks M: 0459 022 445 T: +61 2 8072 1400 E: [email protected] E: [email protected] Media Enquiries Julia Maguire The Capital Network E: [email protected] T: + 61 2 8999 3699 Noxopharm Limited. ABN 50 608 966 123 Suite 3, Level 4, 828 Pacific Highway, Gordon NSW 2072 AUSTRALIA Forward Looking Statements This announcement may contain forward-looking statements. You can identify these statements by the fact they use words such as “aim”, “anticipate”, “assume”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan”, “predict”, “project”, “p lan”, “should”, “target”, “will” or “would” or the negative of such terms or other similar expressions. Forward -looking statements are based on estimates, projections and assumptions made by Noxopharm about circumstances and events that have not yet taken place. Although Noxopharm believes the forward-looking statements to be reasonable, they are not certain. Forward -looking statements involve known and unknown risks, uncertainties and other factors that are in some cases beyond the Company’s control that c ould cause the actual results, performance or achievements to differ materially from those expressed or implied by the forward-looking statement.

The release as fetched from its publisher. noxopharm.com ↗